Scientists at RMW Cho Group Ltd. and Venner Shipley LLP have divulged chlorin K derivatives acting as photosensitizers reported to be used in photodynamic therapy (PDT) and photodynamic diagnosis of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Scientists at Aten Porus Lifesciences Pvt Ltd. and Avammune Therapeutics Inc. have synthesized double-stranded RNA-specific adenosine deaminase (ADAR; ADAR1; IFI-4) inhibitors reported to be useful for the treatment of cancer.

Di’ao Group Chengdu Pharmaceutical Co Ltd. has disclosed DNA-directed RNA polymerase, mitochondrial (POLRMT; MtRPOL) inhibitors reported to be useful for the treatment of cancer.

Shenyang Pharmaceutical University has identified serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.

Hainan Simcere Pharmaceutical Co. Ltd. has patented fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.

The University of Tokyo has synthesized yaku'amide B analogues reported to be useful for the treatment of cancer.

Takeda Pharmaceutical Co. Ltd. has discovered orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, among others.

Tiger Biotherapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to a GTPase KRAS (mutant)-binding moiety through a linker.

Work at Shanghai Meiyue Biotech Development Co. Ltd. has led to the discovery of spiro-heterocycle substituted pyrimidine compounds acting as C-C chemokine receptor type 4 (CCR4) antagonists.